References
1. Jain J, Sutton KS, Hong AL. Progress Update in Pediatric Renal Tumors. Curr Oncol Rep . 2021;23(3):33. doi:10.1007/s11912-021-01016-y
2. Daw NC, Chi Y-Y, Kim Y, et al. Treatment of stage I anaplastic Wilms’ tumour: a report from the Children’s Oncology Group AREN0321 study.Eur J Cancer . 2019;118:58-66. doi:10.1016/j.ejca.2019.05.033
3. Daw NC, Chi Y-Y, Kalapurakal JA, et al. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study. J Clin Oncol . 2020;38(14):1558-1568. doi:10.1200/jco.19.01265
4. Wagner L, Hill DA, Fuller C, et al. Treatment of Metastatic Rhabdoid Tumor of the Kidney. J Pediatric Hematology Oncol . 2002;24(5):385-388. doi:10.1097/00043426-200206000-00012
5. Yamamoto M, Suzuki N, Hatakeyama N, et al. Treatment of Stage IV Malignant Rhabdoid Tumor of the Kidney (MRTK) With ICE and VDCy. J Pediatric Hematology Oncol . 2006;28(5):286-289. doi:10.1097/01.mph.0000212901.84146.5a
6. Marina NM, Poquette CA, Cain AM, Jones D, Pratt CB, Meyer WH. Comparative Renal Tubular Toxicity of Chemotherapy Regimens Including Ifosfamide in Patients With Newly Diagnosed Sarcomas. J Pediatric Hematology Oncol . 2000;22(2):112-118. doi:10.1097/00043426-200003000-00007
7. Santos MLC, Brito BB de, Silva FAF da, Botelho AC dos S, Melo FF de. Nephrotoxicity in cancer treatment: An overview. World J Clin Oncol . 2020;11(4):190-204. doi:10.5306/wjco.v11.i4.190
8. Rossi R, Gödde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol . 1994;12(1):159-165. doi:10.1200/jco.1994.12.1.159
9. Milano GM, Cozza R, Ilari I, De Sio L, Boldrini R, Jenkner A, De Ioris M, Inserra A, Dominici C, Donfrancesco A. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children’s Hospital experience. Cancer . 2006 Apr 15;106(8):1838-45. doi: 10.1002/cncr.21780. Erratum in: Cancer. 2006 Sep 15;107(6):1421. PMID: 16532434.
10. Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E, Laver JH, Reaman GH, Cairo MS. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol. 2002 Mar;13(3):460-9. doi: 10.1093/annonc/mdf028.
11. Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D’Angelo P, Casazza G, Piva L, Luksch R, Perotti D, Pession A, Fagioli F, Dallorso S. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer. 2008 Jul;51(1):23-8. doi: 10.1002/pbc.21524.
12. Ma C, Sridharan M, Al-Sayegh H, et al. Building a Harmonized Datamart by Integrating Cross-Institutional Systems of Clinical, Outcome, and Genomic Data: The Pediatric Patient Informatics Platform ( PPIP ). Jco Clin Cancer Informatics . 2021;5(5):202-215. doi:10.1200/cci.20.00083
13. Venkatramani R, Shoureshi P, Malvar J, Zhou S, Mascarenhas L. High dose alkylator therapy for extracranial malignant rhabdoid tumors in children. Pediatr Blood Cancer . 2014;61(8):1357-1361. doi:10.1002/pbc.25093
14. Sepe DM, Ginsberg JP, Balis FM. Dexrazoxane as a Cardioprotectant in Children Receiving Anthracyclines. Oncol . 2010;15(11):1220-1226. doi:10.1634/theoncologist.2010-0162
15. Jones DP, Chesney RW. Renal toxicity of cancer chemotherapeutic agents in children. Curr Opin Pediatr . 1995;7(2):208-213. doi:10.1097/00008480-199504000-00016
16. Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol . 2002;13(3):460-469. doi:10.1093/annonc/mdf028
17. Daw NC, Gregornik D, Rodman J, et al. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with wilms tumour. Eur J Cancer . 2009;45(1):99-106. doi:10.1016/j.ejca.2008.09.017
18. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor of Bone. New Engl J Medicine . 2003;348(8):694-701. doi:10.1056/nejmoa020890
19. Eaton BR, Claude L, Indelicato DJ, et al. Ewing sarcoma.Pediatr Blood Cancer . 2021;68(S2):e28355. doi:10.1002/pbc.28355
20. Womer RB, West DC, Krailo MD, et al. Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children’s Oncology Group. J Clin Oncol . 2012;30(33):4148-4154. doi:10.1200/jco.2011.41.5703
TABLE 1. Patient characteristics